galcanezumab
galcanezumab: developed by 1 company · 3 clinical trials tracked · 1 FDA decision.
galcanezumab evidence translation
What we can confirm
1 FDA record · 3 tracked trials
What it means
What to watch
Prepared research question
How could galcanezumab → LLY affect its developer, and what evidence supports the link?
Traceable citations · Unknowns marked
See linked entities and source evidence4 indications · 1 study sponsors
Related indications
Study sponsors
Development Pipeline (1)
| Company | Phase |
|---|---|
| ELI LILLY & Co (LLY) For migraine prevention and the treatment of episodic cluste… | Approved |
Clinical Trials (3)
Migraine Medication Effects on Urinary Symptoms
Primary endpoint: changes in OAB symptoms
Prospective Evaluation of Emgality (Galcanezumab) in Breastmilk in Adult Women With Migraine
Primary endpoint: Determine emgality concentration in mature breastmilk
A Randomized, Double-Blind, Placebo-Controlled Study of Galcanezumab in Adolescent Patients 12 to 17 Years of Age With Chronic Migraine - the REBUILD-2 Study
Primary endpoint: Change from Baseline in the Number of Monthly Migraine Headache Days
FDA Decisions1 records
Frequently asked questions
Who is developing galcanezumab?
galcanezumab is being developed by ELI LILLY & Co.
How many clinical trials involve galcanezumab?
BioSniper tracks 3 clinical trials involving galcanezumab.
What is galcanezumab's latest FDA decision?
The most recent tracked FDA decision for galcanezumab is Approval, dated September 27, 2018.